Reprogramming of breast tumor–associated macrophages with modulation of arginine metabolism
Life Science Alliance · 2024-11 · 7 (11) · e202302339
DOI: 10.26508/lsa.202302339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 27.08.2024. Verfasst von Veani Fernando und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell & Cancer Biology, College of Medicine and Life Sciences, University of Toledo Health Science Campus, Toledo, OH, USA. Hauptthemen laut MEDLINE: Arginine, Breast Neoplasms, Tumor-Associated Macrophages, Tumor Microenvironment. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute, American Cancer Society.
Abstract (Originalsprache)
HER2+ breast tumors have abundant immune-suppressive cells, including M2-type tumor-associated macrophages (TAMs). Although TAMs consist of the immune-stimulatory M1 type and immune-suppressive M2 type, the M1/M2-TAM ratio is reduced in immune-suppressive tumors, contributing to their immunotherapy refractoriness. M1- versus M2-TAM formation depends on differential arginine metabolism, where M1-TAMs convert arginine to nitric oxide (NO) and M2-TAMs convert arginine to polyamines (PAs). We hypothesize that such distinct arginine metabolism in M1- versus M2-TAMs is attributed to different availability of BH 4 (NO synthase cofactor) and that its replenishment would reprogram M2-TAMs to M1-TAMs. Recently, we reported that sepiapterin (SEP), the endogenous BH 4 precursor, elevates the expression of M1-TAM markers within HER2+ tumors. Here, we show that SEP restores BH 4 levels in M2-like macrophages, which then redirects arginine metabolism to NO synthesis and converts M2 type to M1 type. The reprogrammed macrophages exhibit full-fledged capabilities of antigen presentation and induction of effector T cells to trigger immunogenic cell death of HER2+ cancer cells. This study substantiates the utility of SEP in the metabolic shift of the HER2+ breast tumor microenvironment as a novel immunotherapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell & Cancer Biology, College of Medicine and Life Sciences, University of Toledo Health Science Campus, Toledo, OH, USA.
- Division of Rheumatology, University of Colorado, Anschutz Medical Campus Barbara Davis Center, Aurora, CO, USA.
- Department of Zoology and Physiology, University of Wyoming, Laramie, WY, USA.
- MetroHealth Medical Center, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, OH, USA.
- Department of Cell & Cancer Biology, College of Medicine and Life Sciences, University of Toledo Health Science Campus, Toledo, OH, USA sxf494@case.edu.
ORCID-Profile: Veani Fernando, Osama Sweef, Saori Furuta
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute
- American Cancer Society
- Ohio Cancer Research
- Medical Research Society
Zitieren
APA
Fernando, V., Zheng, X., Sharma, V., Sweef, O., Choi, E. S., & Furuta, S. (2024). Reprogramming of breast tumor–associated macrophages with modulation of arginine metabolism. Life Science Alliance, 7(11), e202302339. https://doi.org/10.26508/lsa.202302339
Vancouver
Fernando V, Zheng X, Sharma V, Sweef O, Choi ES, Furuta S. Reprogramming of breast tumor–associated macrophages with modulation of arginine metabolism. Life Science Alliance. 2024;7(11):e202302339. doi:10.26508/lsa.202302339
BibTeX
@article{Fernando2024,
author = {Fernando, Veani and Zheng, Xunzhen and Sharma, Vandana and Sweef, Osama and Choi, Eun-Seok and Furuta, Saori},
title = {Reprogramming of breast tumor–associated macrophages with modulation of arginine metabolism},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {11},
pages = {e202302339},
doi = {10.26508/lsa.202302339}
}
EUVIMED